Lena Biosciences

Lena Biosciences is a private biotechnology tools and services company founded in 2016 and based in Atlanta, GA. It operates at the intersection of cell therapy and regenerative medicine, offering a proprietary suite of 3D cell culture platforms and specialized toxicology testing services aimed at de-risking drug discovery. The company's core technology focuses on creating more physiologically relevant in vitro models through perfusion and 3D scaffolding to improve the predictive power of preclinical testing. Its business model combines product sales with fee-for-service contracts, targeting pharmaceutical and biotech companies.

Proprietary 3D cell culture and microphysiological system (MPS) platform featuring the Perfused Organ Panel (a perfused multi-well system using a synthetic hemoglobin blood substitute), the SeedEZ 3D scaffold, and the GradientEZ invasion assay system, designed to create human-mimetic tissue models for drug discovery and toxicology.

Lena Biosciences competes in the organ-on-a-chip and advanced 3D cell culture market with companies like Emulate, Mimetas, CN Bio, and TissUse, as well as larger tools providers such as Corning and Merck. Its differentiation lies in its specific perfusion technology using a synthetic hemoglobin substitute and its integrated product-service model focused on predictive toxicology applications.